Strengthened Leadership, Operational Results, Strategic Collaborations and Protection of Intellectual Property - Research Report

  Strengthened Leadership, Operational Results, Strategic Collaborations and
  Protection of Intellectual Property - Research Report on Hologic, Stryker,
               Life Technologies, Boston Scientific and ResMed

PR Newswire

NEW YORK, July 24, 2013

NEW YORK, July 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Hologic
Inc. (NASDAQ: HOLX), Stryker Corp. (NYSE: SYK), Life Technologies Corporation
(NASDAQ: LIFE), Boston Scientific Corporation (NYSE: BSX) and ResMed Inc.
(NYSE: RMD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Hologic Inc. Research Report

On July 18, 2013, Hologic Inc. (Hologic) announced the appointment of Jack W.
Cumming as President and Chief Executive Officer, effective immediately. Mr.
Cumming commented, "I look forward to working closely with the Board and
leadership team to refine the Company's strategy, enhance performance and
position Hologic to capitalize on the many opportunities ahead. I am confident
we will continue to maintain our leadership role within the industry by
developing cutting edge, state-of-the-art products that address the future
needs of our customers and improve the lives of women." As per the Company,
Mr. Cumming joined Hologic in 2001 and served as Chief Executive Officer from
2001 to 2009. The Full Research Report on Hologic Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/HOLX]

Stryker Corp. Research Report

On July 18, 2013, Stryker Corp. (Stryker) reported its Q2 2013 financial
results with net sales growth of 5% YoY to $2.2 billion. Adjusted diluted net
earnings per share increased 2% YoY to $1.00, while diluted net earnings per
share decreased 34.1% YoY to $0.56. "We delivered another solid quarter of
operational results with balanced sales growth across all segments and
geographies, as well as strong cash flow performance," said Kevin A. Lobo,
President and Chief Executive Officer. "Our earnings per share was impacted by
foreign exchange headwinds which we expect to continue throughout the year."
The Company anticipates full year 2013 sales growth in the range of 5% to 6.5%
in constant currency. The Full Research Report on Stryker Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/SYK]

Life Technologies Corporation Research Report

On July 16, 2013, Life Technologies Corp. (Life Technologies) announced its
collaboration with Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
for current and future companion diagnostics projects. According to Life
Technologies, the collaboration will seek to combine the biomarkers identified
by Merck's translational research with Life Technologies' proprietary platform
technologies and to develop companion diagnostics concurrently with Merck's
drug development programs. "Life Technologies' combination of platforms and
capabilities are unique in the companion diagnostics space, particularly in
oncology," said Ronnie Andrews, President, Genetic & Medical Sciences at Life
Technologies. "By helping pharma target the right cancer patients in clinical
trials, we believe that we have the potential to rapidly accelerate cancer
drug development and this is good for everyone - for Life Technologies and our
pharma partners, and most importantly, for patients." The Full Research Report
on Life Technologies Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/LIFE]

Boston Scientific Corporation Research Report

On July 19, 2013, Boston Scientific Corp. (Boston Scientific) launched a
clinical trial to determine the safety and effectiveness of occipital nerve
stimulation (ONS) using the Precision System in treating chronic migraine,
when used in conjunction with anti-migraine medications. According to Boston
Scientific, the OPTIMISE trial is expected to be used to support various
regulatory approvals of this novel therapy for chronic migraine. "By directly
targeting the occipital nerve with neurostimulation, we are potentially able
to offer patients an effective and relatively low-risk therapy," said Richard
Lipton, M.D., professor of neurology and director of the Montefiore Headache
Center at Albert Einstein College of Medicine in New York and principal
investigator for the study. "I am excited to further evaluate the clinical
utility of the Boston Scientific Precision System with MICC technology as a
treatment for chronic migraine." The Full Research Report on Boston Scientific
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/BSX]

ResMed Inc. Research Report

On July 18, 2013, ResMed Inc. (ResMed) announced that the U.S. government
investigation started at the request of the Company against APEX Medical
Corp., resulted in an administrative law judge at the International Trade
Commission (ITC) determining that the ITC should enter a consent decree
against APEX stopping the importation and sale of infringing APEX products.
"We appreciate but are not surprised by the swift conclusion of this case
against both APEX and Drive Medical Design," said ResMed global general
counsel and chief administrative officer David Pendarvis. "This result is a
testament to the strength of ResMed's intellectual property; our innovation is
a significant market differentiator that puts comfortable and effective
patient care first. We will continue to defend our patents and innovations
against any future threats." The Full Research Report on ResMed Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-22/RMD]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Media Contact: InvestorsReports.com, Kristi Saunders, +1-315-982-6420
(North America)
 
Press spacebar to pause and continue. Press esc to stop.